1-methyl-1,2,3,4-tetrahydroisoquinoline has been researched along with Atherosclerotic Parkinsonism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagatsu, T; Ogawa, M; Suzuki, K; Yoshida, M | 1 |
| Ohta, S; Yamakawa, T | 1 |
2 other study(ies) available for 1-methyl-1,2,3,4-tetrahydroisoquinoline and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues.
Topics: Animals; Biopterins; Caudate Nucleus; Dopamine; Female; Isoquinolines; Levodopa; Male; Neurons; Parkinson Disease, Secondary; Putamen; Saimiri; Structure-Activity Relationship; Substantia Nigra; Tetrahydroisoquinolines; Tyrosine 3-Monooxygenase | 1993 |
Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antipsychotic Agents; Biogenic Amines; Carbolines; Haloperidol; Harmine; Isoquinolines; Male; Mitochondria; Neurotoxins; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Tetrahydroisoquinolines | 1999 |